Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to
severe chronic urticaria who exhibit IgE against thyroperoxidase.